10/14/2009 | CVSS | Cell Genesys, BioSante complete merger; BioSante assumes obligations for 3.125% convertibles
|
6/23/2009 | CVDD | Cell Genesys to buy back most 3.125% convertibles, considers options
|
5/22/2009 | CVDD | Cell Genesys starts exchange for $68.3 million convertible notes
|
5/11/2009 | CV | Cell Genesys will offer to exchange its 3.125% convertibles for new 3.125% convertibles
|
3/9/2009 | CV | Cell Genesys buys back $74.1 million 3.125% convertibles at 60% discount
|
12/17/2008 | CV | Cell Genesys gets tenders for $47.8 million 3.125% convertibles
|
12/2/2008 | CV | Cell Genesys extends Dutch auction tender offer for 3.125% convertibles, ups minimum price
|
11/7/2008 | CV | Cell Genesys starts Dutch auction tender for $80 million 3.125% convertibles
|
10/24/2008 | CV | Cell Genesys buys back $26.3 million 3.125% convertibles at discount
|
8/27/2008 | CV | Market Commentary: Amylin, Cell Genesys fall on product bombshells; Bristol-Myers stands pat; Fannie Mae extends gains
|
2/15/2008 | CV | Market Commentary: Arris hounded by earnings, guidance; Priceline goes other way; Test results boost Cell Genesys
|
11/5/2007 | CV | Market Commentary: American Financial rallies on merger; Ford drives on labor deal; Royal Gold a shiny nugget
|
5/1/2007 | CV | Cell Genesys files $150 million shelf registration
|
4/10/2007 | CV | Market Commentary: Cell Genesys drops on drug speculation; Seagate falls on warning; General Growth, TriZetto launch deals
|
4/3/2007 | CV | Market Commentary: Cell Genesys soars on drug data; Continental gains outright; Digital Realty, Chattem, Borders launch deals
|
3/30/2007 | CV | Market Commentary: Cell Genesys climbs on drug hopes; Eddie Bauer, St. Mary lead new deals; RF Micro, Strategic Hotels trail
|
9/8/2006 | CV | Market Commentary: National Retail gains on debut; Cell Genesys takes comfort in stock sale; AirTran dives on lowered outlook
|
5/10/2006 | CV | Market Commentary: SanDisk, Broadwing climb on debuts; Amkor, JDS Uniphase, Manor Care plan deals; Teva steady on loss
|
12/15/2005 | CV | Market Commentary: ON Semi, OSI Pharma at bat; Entergy goes to 50.5 bid; Intel steady; Abgenix issues climb
|
5/11/2005 | CV | Market Commentary: Delta bankruptcy seen inevitable; GM, Ford weigh financials, IPG; KV Pharma slammed; Red Hat up
|
11/17/2004 | CV | Cell Genesys greenshoe exercised, raising convertibles to $145 million
|
10/18/2004 | CV | Market Commentary: Sirius convertibles up on Ford news; Elan active, edges up on Biogen buzz; CNet gains
|
10/15/2004 | CV | New Issue: Cell Genesys upsized $110 million convertible at 3.125%, up 30%
|
10/15/2004 | CV | Market Commentary: Shoppers look for bargains among insurance rubble; Shanda up; Cell Genesys off
|
10/14/2004 | CV | Market Commentary: Shanda, Cell Genesys bid up in gray market; insurers pulverized by Spitzer suit
|
10/12/2004 | CV | Cell Genesys $100 million convertible talked at 2.625%-3.125%, up 30%-35%
|
10/12/2004 | CV | Market Commentary: Apex Silver hovers around par; Amkor firms as bids hit; NPS Pharma, biotechs suffer
|